When is a Bentall aortic root replacement indicated, which conduit type is appropriate for different patient ages, and what are the essential intra‑operative and postoperative management recommendations?

Aortic Root Replacement: Indications, Conduit Selection, and Management

Indications for Bentall Procedure

Bentall aortic root replacement is indicated when aortic root aneurysm ≥5.0 cm is present with concomitant aortic valve disease requiring replacement. 1

Size-Based Indications

The primary threshold for intervention is:

• Aortic root diameter ≥5.0 cm in most patients 1
• Indexed aortic size ratio ≥10 cm²/m (maximal cross-sectional area divided by patient height) provides an alternative metric that accounts for body size variation 1

Earlier Intervention Criteria (diameter <5.0 cm)

Consider surgery at smaller diameters when:

• Rapid aortic growth ≥0.3 cm/year 1
• Family history of aortic dissection 1
• Severe aortic valve regurgitation requiring intervention 1
• Desire for pregnancy in women with connective tissue disorders 1
• Marfan syndrome with additional risk factors 1

Emergency/Urgent Indications

• Acute Type A aortic dissection involving the root
• Symptomatic aneurysm
• Acute aortic regurgitation with hemodynamic compromise

---

Conduit Selection by Patient Age

The choice between mechanical composite graft (Bentall), bioprosthetic composite graft (Bio-Bentall), and valve-sparing root replacement (David procedure) depends primarily on patient age, anticoagulation tolerance, and valve anatomy. 1, 2

Age-Based Algorithm

Patients <50 years:

• First choice: Valve-sparing root replacement (David procedure) if native valve is suitable (avoids lifelong prosthetic valve complications) 1
• Second choice: Mechanical Bentall if valve cannot be preserved and patient can tolerate anticoagulation 2
• Third choice: Ross procedure (pulmonary autograft) at experienced Comprehensive Valve Centers for select patients preferring biological option 2

Patients 50-65 years:

• Individualized decision between mechanical and bioprosthetic Bentall based on:
  • Anticoagulation contraindications or patient preference against warfarin → Bio-Bentall 2
  • No anticoagulation concerns and desire to avoid reintervention → Mechanical Bentall 2
  • Suitable valve anatomy → Consider David procedure 1, 3

Patients 60-75 years (sexagenarians):

• Bio-Bentall is reasonable as primary option 2, 3
• David procedure remains viable with excellent outcomes: 10-year survival 87% vs 80% for Bio-Bentall, with superior cardiac-specific survival (98% vs 92%) and lower rates of endocarditis and permanent pacemaker implantation 3

Patients >65 years:

• Bio-Bentall is preferred over mechanical valve 2
• Bioprosthetic conduits show acceptable durability with linearized death rates similar to age-matched populations 4

Critical Conduit Selection Considerations

Anticoagulation contraindications at any age mandate bioprosthetic valve selection 2. This includes:

• History of major bleeding
• High fall risk
• Inability to maintain therapeutic INR monitoring
• Patient refusal of lifelong anticoagulation

Valve-sparing (David) procedure requirements:

• Competent aortic valve leaflets without significant structural abnormality
• No severe calcification
• Experienced surgical team at high-volume center 1
• Accept 7% risk of ≥moderate AR at 1 year in Marfan patients 1

---

Intraoperative Management Essentials

Cannulation Strategy

For giant aortic root aneurysms (>10 cm), perform axillary artery cannulation with early heparinization BEFORE sternotomy to enable immediate cardiopulmonary bypass if rupture occurs 5. This is a critical safety measure for high-risk cases.

For standard cases:

• Central aortic cannulation if ascending aorta is suitable
• Femoral or axillary cannulation for dissection or friable tissue

Technical Execution

The modified Bentall procedure involves:

1. Composite valved graft conduit (mechanical or bioprosthetic valve sewn to Dacron graft)
2. Proximal anastomosis to left ventricular outflow tract
3. Coronary button reimplantation into graft 1, 6
4. Distal anastomosis to ascending aorta
5. Both aortic root AND ascending aorta are replaced together 1

For Bio-Bentall, position the biological valve INSIDE the vascular graft rather than at the proximal end—this allows future valve-in-valve replacement without disturbing coronary ostia if structural valve deterioration occurs 4.

Valve oversizing is achievable with the Bio-Bentall technique: patients with annulus ≤23 mm can receive valves averaging 26.3 mm, improving hemodynamics 4.

Hemostasis Considerations

• Meticulous hemostasis at coronary button anastomoses
• Bio-Bentall grafts demonstrate excellent hemostatic characteristics with 37.9% of patients requiring no blood transfusion 4
• Rethoracotomy for bleeding occurs in approximately 4.4% of cases 4

---

Postoperative Management Priorities

Immediate Postoperative Period

Monitor for:

• Bleeding complications (most common early complication requiring reintervention) 4, 7
• Neurologic complications (higher with mechanical valves/Bio-Bentall vs David procedure) 3
• Conduction abnormalities requiring permanent pacemaker (significantly higher with Bio-Bentall: monitor closely) 3

Anticoagulation Management

Mechanical Bentall:

• Initiate warfarin therapy targeting INR 2.5-3.5 (mechanical aortic valve)
• Bridge with heparin until therapeutic INR achieved
• Lifelong anticoagulation mandatory

Bio-Bentall:

• Aspirin 81-100 mg daily
• Consider 3 months warfarin for large grafts or atrial fibrillation
• No long-term anticoagulation required

David procedure:

• Aspirin therapy
• No anticoagulation unless other indication

Long-Term Surveillance

All patients require lifelong imaging surveillance:

• Baseline postoperative CT angiography or MRI
• Annual imaging for first 5 years
• Biennial imaging thereafter if stable
• Monitor distal aorta (arch, descending, abdominal segments) as these may dilate over time, especially in Marfan syndrome 1

Echocardiographic follow-up:

• Assess valve function (especially for David procedure—7% develop ≥moderate AR at 1 year) 1
• Monitor LV function recovery
• Evaluate for endocarditis (higher risk with mechanical valves)

Medical Therapy

Beta-blocker therapy should be continued lifelong in patients with:

• Marfan syndrome
• Connective tissue disorders
• Residual aortic disease

Target heart rate <60-70 bpm and systolic blood pressure <120 mmHg to reduce aortic wall stress.

---

Critical Pitfalls to Avoid

1. Do not delay surgery in patients meeting size criteria—dissection risk increases substantially >5.0 cm 1

2. Do not perform isolated ascending aorta replacement when root is dilated—both root AND ascending aorta must be replaced together 1

3. Do not choose mechanical valve in patients >65 years unless specific compelling reason—bioprosthetic is preferred 2

4. Do not attempt David procedure with unsuitable valve anatomy or at inexperienced centers—results depend heavily on surgical expertise 1

5. Do not forget to surveil distal aorta postoperatively—20% of Marfan patients develop distal aortic pathology requiring intervention 1

6. For giant aneurysms, do not perform sternotomy before establishing alternative cannulation access—have bypass capability ready before opening chest 5

---

Surgical Risk and Outcomes

When performed by experienced surgeons in Multidisciplinary Aortic Teams, aortic root replacement carries very low surgical risk 1. Contemporary series report:

• In-hospital mortality: 0.5-2.6% 4, 7
• 10-year survival: 74-87% depending on technique and patient age 4, 3
• Cardiac-specific survival superior with David procedure (98% vs 92% at 10 years) 3

The procedure should be performed at high-volume centers with dedicated aortic surgery expertise to achieve optimal outcomes 1, 2.